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Abstract
Background: This report describes the methods utilized in the Penn Ovarian Aging Study (POAS), which is a
longitudinal cohort study of hormone dynamics and menopausal symptoms of women in the menopause
transition.
Methods/Design: The cohort is a community-based sample of generally healthy women enrolled in the late
reproductive years. The study population is a stratified random sample of African-American and Caucasian women,
identified by random digit dialing.
Of the 1427 women who were identified as potentially eligible, 578 women were eligible after full screening; 75 % of
the eligible women enrolled in the study (436/578). At Period 14 (14 years after study enrollment), 67 % remained active
and were fully evaluated (293/436). Attrition was non-differential with respect to the sample characteristics.
The aims of the project overall are to 1) identify within-woman trends of reproductive hormones (estradiol, follicle
stimulating hormone, hormone, lutinizing hormone, inhibin B, dehydroepiandrosterone, testosterone, and anti-mullerian
hormone), cofactors such as race, body mass index (BMI), age, physical and behavioral symptoms, and their predictions
of menopausal symptoms, and patterns around the final menstrual period; 2) identify associations of hormone dynamics
with physical and behavioral symptoms that occur with ovarian aging and identify racial differences in these factors; 3)
identify associations of genetic polymorphisms with levels and longitudinal trends in menopausal symptoms. The cohort
consists of 436 late reproductive-age women at enrollment, and now has 18 years of approximately annual follow-up
assessments. Menopausal stage based on concurrent menstrual dates is identified at each follow-up period.
Discussion: Studies of the cohort have shown that hot flashes can occur well before menopause and extend 10 or
more years beyond menopause for sizeable numbers of women; provide evidence for new-onset depressed
mood in the menopause transition and show that the final menstrual period is pivotal in the increases in
depressive symptoms prior to menopause and decreases postmenopausal; suggest that poor sleep is common in
the late reproductive years but increases in relation to the final menstrual period in only a small proportion of
women; and show effects of obesity on reproductive hormones in the menopause transition. To date, more than
50 studies of the cohort are published in medical journals, demonstrating the relevance of these data to the
clinical care of mid-life women.
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Background
More than 80 % of U.S. women experience physical or
behavioral symptoms around menopause, most com-
monly hot flashes and night sweats, depressive symp-
toms, and sleep disturbances [1]. Although the severity
of these symptoms varies widely, many women seek
medical relief for distressing symptoms that disrupt
their functioning. However, whether these symptoms
are associated with the biological changes of ovarian
senescence or with age-related changes and other be-
havioral and psychosocial conditions of mid-life has
only recently been a target of scientific investigation,
and knowledge of the efficacy of therapeutic treatments
is limited.
Calls for research have aimed to increase understand-
ing of biological and behavioral changes associated with
ovarian aging, and to identify whether there are racial
differences in these changes. Recent cohort studies of
mid-life or late reproductive age women are elucidating
associations between symptoms and reproductive aging
and providing new information that can lead to better
preventive and therapeutic strategies and reduce the
short- and long-term morbidity of women’s mid-life and
postmenopausal years.
The purpose of this report is to describe the methods in
the Epidemiologic Study of the Late Reproductive Years,
which is also termed the Penn Ovarian Aging Study
(POAS), supported by the National Institute of Aging
(RO1-AG12745). The POAS cohort consists of healthy,
mid-life women in their late reproductive years, who were
randomly identified through random digit dialing in Phila-
delphia County, Pennsylvania, with stratification to obtain
equal numbers of African American and Caucasian women.
The cohort has continued for 18 years with approximately
annual follow-up evaluations.
POAS studies focus on hormone dynamics and associ-
ated symptoms of menopause. The participants were
premenopausal at enrollment and then entered and
moved through stages of the menopause transition. The
overall aims of the project are to 1) identify how within-
woman trends of reproductive hormones (estradiol, fol-
licle stimulating hormone, luteinizing hormone, inhibin
B, dehydroepiandrosterone, testosterone, and anti-
mullerian hormone) and cofactors such as race, body
mass index (BMI), age, physical and behavioral symp-
toms predict the progression through the menopause
transition; 2) identify associations of hormone dynamics
with physical and behavioral symptoms that occur with
ovarian aging and identify racial differences in these fac-
tors; 3) compare hormone levels and longitudinal trends
between African American and Caucasian women; 4)
identify associations of genetic polymorphisms with
levels and longitudinal trends and with menopausal
symptoms.
Methods
Overview of study design
This longitudinal study has 14 complete assessment pe-
riods followed by 4 partial assessment periods for a total
of 18 assessment periods. In each full assessment period,
data were collected at 2 visits scheduled between days 2
and 6 of 2 consecutive menstrual cycles (or 1 month
apart in non-cycling women). In the first five years of
the project (Phase 1), the follow-up assessment periods
were approximately 9 months apart. In Phase 2 (years
6–10) and Phase 3 (years 11–15), follow-up assessments
were conducted annually. There were 14 complete as-
sessment periods due to a one-year delay in funding in
year 11. Limited follow-up was conducted annually by
telephone interview for follow-up periods 15–17. Full
follow-up with home visits was resumed in year 18.
Study visits were conducted at participants’ homes. At
each visit, a trained research interviewer administered a
structured interview questionnaire and obtained anthropo-
metric measures and blood samples for the hormone
assays. Participants also completed standard self-report
questionnaires to assess physical, behavioral and mood
factors and completed a daily symptom report for 1
menstrual cycle at each assessment period.
Sample selection and recruitment
A sample of 436 healthy women (218 African American,
218 Caucasian) was recruited in Philadelphia County
over a 16-month period in 1996–1997. Recruitment was
stratified by race to obtain equal numbers of African
American and Caucasian participants. In a two-phase re-
cruitment process, potentially eligible women were first
identified through random-digit dialing, using a modified
Mitoksky-Waksberg method [2]. The women who were
identified through random digit dialing were then contacted
by a research interviewer, who explained the details of the
study and screened for study eligibility.
Women were eligible for study participation if they
were between 35 and 47 years of age, experienced regu-
lar menstrual cycles in normal range (22–35 days) in the
past 3 months, and had at least one ovary and a uterus.
Women were excluded from enrollment if they were preg-
nant, taking hormone therapy or using hormonal contra-
ception, taking psychotropic medications, had a history of
illness that could affect hormonal function (e.g., diabetes,
liver disease, breast or endometrial cancer, et al.), had a
history of drug or alcohol abuse or a major psychiatric dis-
order in the previous 12 months, or were non-English
speaking.
The age range was carefully considered when the cohort
was recruited in order to evaluate ovarian aging prior to
observable menstrual cycle changes. The lower age limit of
35 years was selected as an age when follicular depletion
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accelerates, resulting in subtle increases in follicle-
stimulating hormone (FSH) and decreases in inhibin
[3], and is consistent with standard age groupings as in
U.S. census data (e.g., ages 35–39 years). The upper age
limit of 47 years was selected as an accepted median
age for women entering the perimenopause, as shown
in the estimates of Treloar [4] and McKinlay [5]. This
provided a unique baseline of premenopausal women for the
subsequent follow-up through the menopause transition.
A cohort size of N = 300 women (150 in each racial
group) was predetermined using a 2-sided alpha error of
0.05 and 80 % power to detect clinically relevant differ-
ences in hormones and symptoms. The enrollment num-
ber was increased to 436 women to account for estimated
dropout in the first 4 years of the study. However, it is
noteworthy that retention far exceeded the initial estimate
(see below), and the powered estimate of 300 participants
remained at Year 12. Further post-hoc calculations of stat-
istical power for hypothesis testing have remained strong
throughout the years of the study.
To obtain the cohort of 436 women, 1427 potentially
eligible women were identified through random digit
dialing. Of these, 129 (9 %) could not be contacted fur-
ther by the research staff, 308 (22 %) declined to partici-
pate without providing eligibility information, and 412
(29 %) were ineligible. Reasons for ineligibility included
hysterectomy (n = 111), use of hormonal contraception
(n = 87), menstrual irregularities or no menses (n = 92),
known to be leaving the area during the study period (n =
31), medical contraindications (n = 30), pregnant, breast
feeding or attempting pregnancy (n = 24), alcohol or drug
abuse (n = 6). Of the 578 women eligible after full screen,
436 (75 %) enrolled, and 142 (25 %) declined. Neither eli-
gibility nor participation differed significantly by race.
Informed consent for study participation and follow-up
contact was approved by the Institutional Review Board of
the University of Pennsylvania, signed and witnessed at
the first study visit and repeated thereafter when there
were protocol changes (e.g., the addition of another
hormone assay). Verbal consent was given for telephone
contacts in the screen period and at later follow-up
telephone contacts.
Sample characteristics at enrollment
Four- hundred-thirty- six women enrolled in the cohort
(218 African American, 218 Caucasian). All participants
were premenopausal with regular menstrual cycles in
normal range (22–35 days) at enrollment. The mean age
was 41.4 (SD 3.5) years (range 35–47 years). The mean
cycle day of the blood draw was 4.0 (SD 1.0). Mean (SD)
hormone levels were FSH: 8.3 (5.2) mIu/mL; inhibin b:
78.0 (77.0) pg/mL; LH: 3.4 (2.6) mIU/mL; estradiol: 44.1
(38.8) pg/mL. [6]. The mean BMI was 29.1; 38 % (166/436)
were current smokers; 81 % were employed; 33 % were
high school graduates, 11 % had less than high school
education, 56 % had college or technical training be-
yond high school; 57 % were married, 43 % were single,
divorced, separated or widowed.
Data collection
a. Interview questionnaire. A structured interview ques-
tionnaire was constructed and tested for the study and
administered by a trained research interviewer at the
first visit of every assessment period. Primary components
of the interview included standard demographic informa-
tion; menstrual cycle characteristics (most importantly,
the dates of the current and previous two menstrual pe-
riods); menopausal symptoms (using a validated menstrual
symptom questionnaire [7], which were reported for the
past month and the past year and included frequency and
severity of each symptom; general and gynecological
health (current, history and contraceptive use), all current
medications; health practices and behaviors (including
smoking and alcohol consumption); physical activity
(adapted from the validated College Alumni Health
Study questionnaire [8] with additional questions such
as number of city blocks walked daily, etc., that are
shown to be a major source of physical activity among
African American women [9]; sleep disturbance (using
the validated St Mary’s Hospital Sleep Questionnaire
[10, 11]; decreased functioning due to symptoms (using
the Sheehan Disability Scale [12]).
b. The Menopausal Symptom List (MSL) [7]. This vali-
dated symptom list included 12 common menopausal
symptoms: hot flashes/night sweats; aches/joint pain/
stiffness; depressed mood; poor sleep; decreased libido;
vaginal dryness; urine leaks; headache; irritability; mood
swings; anxiety; and concentration difficulties. The symp-
tom list was embedded in the structured Interview Ques-
tionnaire and administered by the research interviewer at
each assessment period (periods 1–18). For each symptom,
the interviewer asked whether the symptom occurred in
the past month, whether the symptom occurred in the
past year, and asked the participant to rate the frequency
(number per day, week or month) and severity (none,
mild, moderate, severe) of each symptom. The MSL was
validated for the study [7], and several reports of associa-
tions between the symptoms and menopausal stages are
published [13, 14].
c. Mood and anxiety diagnosis. Current mood disorders
were screened for all women at enrollment using the
Symptom-Driven Diagnostic System (SDDS-PC) [15],
which was developed from the Structured Clinical
Interview for DSM III R Diagnosis (SCID) [16]. The
SDDS is a validated screening measure for DSM diag-
noses of major mood disorders, its symptom checklist
is rapid and easily used by the participants, it provides
symptom information collected systematically from all
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participants, and the screening information can be ob-
tained in the telephone interview followed by in-person
evaluation of screen positives at the next study visit.
Clinical diagnosis was made using the Primary Care
Evaluation of Mental Disorders (PRIME-MD) [17] to ob-
tain DSM diagnoses of depression and anxiety disorders
at each assessment period through Period 6. The Prime-
MD is a 2-stage system where the participant first com-
pletes a 26-item self-administered questionnaire that screens
for 5 of the most common groups of disorders in primary
care: depressive, anxiety, alcohol, somatoform and eating
disorders. Algorithms are provided, and when the checklist
scores indicate a defined severity level, trained interviewers
administer a brief set of questions to determine a DSM
diagnosis. The Prime-MD is validated and highly corre-
lated with full SCID interviews for DSM diagnosis.
The Patient Health Questionnaire (PHQ) [18] was ad-
ministered in Periods 7 through 14. The PHQ is a self-
administered version of the Prime-MD to provide DSM
diagnosis of major depressive disorder, other depressive
syndromes, panic disorder, other anxiety syndromes, eat-
ing disorder and alcohol abuse. It also queries bothersome
problems, current medications and reproductive events.
The PHQ is extensively validated and has a sensitivity of
0.88 and specificity of 0.88 for the diagnosis of MDD [19].
d. Behavioral symptom measures. Six self-report
questionnaires were completed by the participants at
each assessment period. All measures are validated
and published in the literature.
Depressive symptoms were evaluated at each assess-
ment period using the Center for Epidemiologic Studies
Depression Scale (CES-D) [20]. The CES-D is a 20-item
self-report inventory that was developed for epidemiologic
research, is widely used and validated. The standard
CES-D cutoff score of 16 or greater indicates high de-
pressive symptoms. A higher CES-D score of 25 or greater
can be examined as a closer approximation of a clinical
diagnosis of depression [17, 21].
Anxiety symptoms were evaluated at every assessment
period using the Zung Anxiety Index, a validated, 20-item
self-report measure that is sensitive to the frequency of
both affective and somatic symptoms of anxiety [22].
Zung established score ranges to classify normal anxiety
[20–35], mild to moderate anxiety [36–47], and high
anxiety (48–60).
Perceived stress was evaluated using the Perceived Stress
Scale (PSS) [23] at each assessment period. The PSS is a
14-item widely validated self-report measure of the degree
to which situations are appraised as stressful.
Quality of life was evaluated with the Quality of Life
Enjoyment and Satisfaction Questionnaire (Q-les-Q) [24],
which assesses various aspects of quality of life. The
16-item summary scale was used in this project. The
Q-les-Q has high reliability and validity, addresses
general functioning rather than disease-specific issues,
and has considerable normative data available. The
Utian Quality of Life Scale (UQOL) [25] was added in
Periods 11–14. This validated instrument is specific to a
perimenopausal population and quantifies “sense of well-
being”.
General health. The SF-12 Health Survey [26] was ad-
ministered at each assessment period to monitor health
outcomes. The SF-12 is a 12-item short form developed
from the SF-36 Health Survey. There are two summary
scales, which have demonstrated equivalence to the
SF-36 and yield reliable summary scales for physical
and mental health.
e. Sleep disturbance. The St. Mary’s Hospital Sleep
Questionnaire (SMHSQ) [11], a standard, self-administered
questionnaire, was administered to assess sleep disturbances
at each assessment period through Period 8. We adapted
the SMHSQ by adding items to assess the etiology of noc-
turnal awakenings, the frequency of sleep medication use,
and whether the previous night of sleep was comparable to
usual sleep and deleting items about bedtime, fall-asleep
time, wake time, time out of bed, and the “depth” of sleep,
resulting in a total of 20 items.
We subsequently conducted a factor analysis of the
SMHSQ, using all data from the first assessment period
[27]. The factor analysis identified 3 factors: sleep quality,
sleep complaints, and sleep latency. The sleep quality
factor explained the largest proportion of variability in
responses (37 %) and was used as a primary outcome
variable for sleep studies in the cohort [27, 28].
“Poor sleep” (frequency and severity) was included as
a symptom in the validated menopausal symptom ques-
tionnaire, administered at each assessment period through
18 years of follow-up [7]. This sleep item had a high cor-
relation with the sleep quality factor score derived from
the SMHSQ (r = 0.83) [27] and has been used as a primary
outcome measure in sleep studies in this cohort [28, 29].
The Women’s Health Initiative Insomnia Rating Scale
(WHIIRS) [30] was collected in assessment periods 10–14.
The WHIIRS is a 5-item self-report questionnaire that is
sensitive to sleep disturbances over time and validated in a
perimenopausal population. The Multivariable Apnea
Prediction Index (MAP) [31] was administered in Periods
10–14).
f. The Female Sexual Functioning Index (FSFI) [32]
was collected in each assessment period 8–14. The FSFI
is a 19-item, multi-dimensional, self-report instrument for
assessing the key dimensions of sexual function in women.
Domains include desire, arousal, lubrication, orgasm,
satisfaction, and pain. The instrument has been validated
and scaled on a sample of women with clinically diagnosed
female sexual dysfunction.
Symptoms of decreased libido and vaginal dryness
were included in the validated Menopausal Symptom
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Questionnaire, administered by interview at each assess-
ment period. The items were “Please tell me if you have
experienced a decreased libido or interest in sex in the
past month” and “Have you experienced vaginal dryness
or discomfort in the past month.”
A 30-day and a 1-year time period were queried; partici-
pants rated the severity (none, mild, moderate, severe)
and the frequency of the items.
g. The Social Adjustment Scale (SAS) [33] was com-
pleted by participants at assessment Periods 1–3, 6–8,
and 11–13. The scale provides domain scores that evalu-
ate the participant’s role performance, interpersonal rela-
tionships, friction, feelings and satisfaction in work, and
social and leisure activities
h. Cognition. Brief tests of cognitive memory were com-
pleted at each assessment period. These included the
Buschke-Fuld Selective Reminding Test [34], which pro-
vided scores for total recall, short-term recall and long-
term storage; the Digit Symbol Substitution test (Weschler
Adult Intelligence Test-III) [35], a sensitive measure of
cognitive processing speed [36]; and the Digit Symbol
Copy test (WAIS-III) [35] to assess sensorimotor pro-
cessing speed. These are widely used, brief cognitive
tests, with extensive data published in the literature.
i. Daily Symptom Reports (DSR) were completed by
participants for one menstrual cycle (or one month if
not cycling) at each assessment period to determine pro-
spectively the occurrence and severity of symptoms in
relation to the menstrual cycle. The DSR lists 20 symp-
toms specific to reproductive aging as described in the
menopause literature. Participants rated the symptoms
daily on a 5-point scale of severity according to written
descriptors (0 = not present to 4 = very severe). The
symptoms included on the DSR were also included in
the Menopausal Symptom List (above), which was ad-
ministered by interview at each assessment period.
j. Anthropometric measures. Measures of height, weight,
waist and hip circumferences were made at each assess-
ment period 1–14. Height (without shoes) was measured
to the nearest 0.5 cm with a vertical ruler. Body weight
(light clothing only) was measure to the nearest 0.2 kg.
Waist circumference was measured at the maximum ab-
dominal girth, in duplicate, to the nearest 0.5 cm. Hip cir-
cumference was measured at the maximal protrusion of
the hips at the level of the symphysis pubis, in duplicate,
to the nearest 0.5 cm. The average of duplicate measures
was calculated for analysis.
Body mass index (BMI) was calculated by computer
algorithm from the measures of height and weight at
each assessment period, using the average of the dupli-
cate measures of height and weight at each assessment
period (weight (kg) divided by the square of height (cm).
k. Hormone measures. Blood samples were obtained at
each study visit (2 visits per assessment period). Visits
were scheduled throughout the day in days 2–6 of the
menstrual cycle or approximately one month apart in
the assessment period for non-cycling women. Standard-
izing the collection of blood samples to the first 6 days
of the menstrual cycle was maintained for cycling women
throughout the project. Less than 1 % of the blood sam-
ples from cycling women were outside the 6-day window.
Blood samples (2 ½ ounces, non-fasting) were drawn
from the non-dominant arm into vacutainer serum separ-
ator (tiger top) tubes containing separator gel and clot ac-
tivator. The tubes were kept on ice, centrifuged for 20 min
and frozen in aliquots (−80 C.) using polypropylene tubes.
Hormone values were measured by radioimmunoassay
in the Clinical and Translational Research Center
(CTRC) of the University of Pennsylvania. Assays were
conducted in batched samples of 20 participants, with 4
samples at 4 time points per participant, to reduce the
within-subject variability due to assay conditions. Estra-
diol, follicle stimulating hormone (FSH), luteinizing
hormone (LH), dehydroepiandrosterone (DHEAS), tes-
tosterone, and sex hormone binding globulin (SHBG)
were assayed using commercial kits (Coat-a-Count, Diag-
nostic Products Corp). Anti-mullerian hormone (AMH) as-
says were conducted using ELISA commercial kits (GEN 2,
Beckman Coulter). Assays of Inhibin b were initially con-
ducted in the laboratory of Dr. Patrick Sluss (Massachusetts
General Hospital, Boston, MA) (assessment periods 1–
10), and then conducted in the CTRC (assessment pe-
riods 11–14) using a commercial kit (Diagnostic Sys-
tems). Assays were performed in duplicate for all
hormones and repeated if values differed by more than
15 %. Inter- and intra-assay coefficients of variation were
calculated for the study samples in each study phase and
were consistently less than 5 %.
l. Genomic DNA and genetic polymorphisms. Genomic
DNA was obtained from 95 % of the cohort (413/436).
Extraction of genomic DNA was performed using the
QIAamp 96 DNA Buccal Swab Biorobot Kit and per-
formed on a 9604 Biorobot (Qiagen, Inc., Valencia, CA).
We identified seven genes involved in the downstream
metabolism of estrogen and chose functionally relevant
SNPs with a sufficiently high allele frequency to provide
adequate power for testing first order interactions in the
cohort. These SNPs were: COMT Val158Met (rs4680),
CYP19 Arg 264Cys, (re700519), CYP1A2*1 F (rs762551),
CYP1B1*4 (Asn452Ser, rs1800440), CYP1B1*3 (Leu432-
Val, rs1056836), CYP3A4*1B (rs2740574), SULT1A1
Arg213His (*2; rs9282861), SULT1A1*3 (Met223Val,
rs1801030), SULT1E1 (−64G > A Promoter Variant;
rs3736599), and SULT1E1 A220G 3’UTR Variant
(rs3786599). Genotypes were determined using previously
described methods [37, 38].
m. Other behavioral measures. Additional validated
behavioral measures were included at selected assessment
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periods to assess variables for pre-specified studies. The
validated Kaiser Physical Activity Survey (KPAS) [39] was
included in Periods 13–14. The Bristol Female Lower
Urinary Tract Symptoms Scored Form (BFLUTS-SF) [40]
was administered at Periods 11–14. A 61-item Dietary As-
sessment Questionnaire (DAQ) from the Nurses’ Health
Study [41] was completed by participants at Periods 2, 5,
6, 7, and 9. Table 1 presents a summary of the outcome
measures by study visits.
Definition of menopausal status
We defined 5 stages of the menopause transition based
on menstrual bleeding patterns and adapted from the
initial Stages of Reproductive Aging Workshop (STRAW)
[42] in order to capture the early changes in the meno-
pausal transition [43]. The following 5 categories were de-
fined in the cohort: 1) Premenopausal: regular menstrual
cycles in the 22–35 day range. (Note: all participants were
premenopausal at cohort enrollment). 2) Late premeno-
pausal: a change in cycle length of 7 days or more in either
direction from the participant’s personal baseline at enroll-
ment in the cohort and observed for at least one cycle in
the study. 3). Early transition: changes in cycle length of
7 days or more in either direction from the participant’s
personal baseline at enrollment in the cohort and ob-
served for at least 2 consecutive cycles in the study or
60 days amenorrhea. 4). Late transition: more than 60 days
to 11 months amenorrhea. 5). Postmenopausal: 12 months
or more amenorrhea, excluding hysterectomy. As partici-
pants progressed beyond menopause, the number of years
since the final menstrual period were identified for ana-
lysis of the postmenopausal stage. Analyses have been
conducted comparing early and later postmenopause as
follows: <2 versus > =2 years [44]; 0–3 versus >3–11 years
[45]; 0–5 versus 6–14 years [46].
Menopausal stage was identified at each assessment
period, using the menstrual dates recorded at each study
visit. This included the date of the current menstrual
cycle (visits were conducted within 6 days of bleeding)
and the dates for the 2 previous menstrual cycles, which
were recorded at each visit. The 6 dates recorded at 2
visits provided consecutive menstrual dates for approxi-
mately 4 months in each assessment period. Additional
confirmatory data were obtained from the daily symp-
toms diaries that participants recorded for one menstrual
cycle at each assessment period (the diary date was used
in cases of disagreement). Other confirmatory data in-
cluded the reported number of menstrual periods between
assessments, cycle length and the number of bleeding
days, which were obtained in the structured interviews
and the daily diaries.
Hormonal contraception, hysterectomy, pregnancy and
breast feeding were exclusions at study enrollment. When
these events occurred during the study, the information
was coded and menopausal stage for these subjects was
classified separately in categories of “hysterectomy”,
“hormone use”, and “pregnancy/breast feeding” in the
relevant assessment periods.
Identification of final menstrual period (FMP)
The final menstrual period was identified retrospectively
after 12 or more months of no menstrual bleeding. The
FMP marked entry into the postmenopausal stage. The
small number of participants with surgical menopause
were categorized separately.
Study adherence and attrition
Attrition occurred primarily in the early years of the
study (Table 2). Nineteen percent (83/436) discontinued
in the first 6 years. Half of these discontinued in the first
year of the study, when they refused further participation
or could not be located for the first follow-up evaluation.
Only 10 % (42/436) discontinued in Phase 2 (years 7–10),
and 4 % (18/436) discontinued in Phase 3 (years 11–14),
for a total of 33 % attrition (143/436) over 14 years. Attri-
tion through Period 14 was classified as lost to follow-up
(n = 51), no reason given (n = 40), withdrew consent (n =
22), personal constraints or problems (n = 16), and de-
ceased (n = 14).
We conducted a systematic analysis of study participa-
tion in the first 4 years, as reported in Nelson et al. [47].
Nelson examined demographic, behavioral, psychosocial
and hormonal variables of the study that included age,
race (African-American and Caucasian), education, marital
status, body mass index, depressive symptoms, menopausal
symptoms, perceived stress, anxiety, and reproductive hor-
mone levels. There were no racial differences in study par-
ticipation. Reproductive hormone levels at baseline did not
differ between active and dropout groups. Only 2 variables
marginally differed between active participants and drop-
outs: the dropout group was less likely to have high school
education and less likely to report menopausal symptoms.
Attrition to date has not significantly differed by race.
Effect of attrition on power
The pre-enrollment estimates for sample size indicated
that a cohort of 300 women would detect clinically
relevant differences in hormones and symptoms, using
a 2-sided alpha error of 0.05 and 80 % power. We en-
rolled 436 women based on estimates of attrition in the
first 4 years of the study. At the 12-year follow-up, 300
participants remained active and 293 participants
remained active at Year 14.
We consider the home visits to be the key element in
maintaining the high completion rate, which has far
exceeded the original estimates. All data and blood sam-
ples were collected at home visits from enrollment
through Period 14, resulting in minimal missing data
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Table 1 Outcome measures by study visits
Domain Measure Study visits1
Demographic Interview questionnaire 1,3,5,7,9,11,13





Menopausal symptoms Symptom questionnaire5 all odd visits 1-27





Interview questionnaire all odd visits 1-27
General SF-12 Health Survey24 all odd visits 1-27
Physical activity Questionnaire6 4,12,16,20,22,24,25,27
Kaiser Physical Activity Survey37 25,27
Sleep SMH Sleep Questionnaire8,9 1,3,5,7,11,13,15,19
WHI Insomnia Rating Scale28 19,21,23,25,27
Apnea Prediction Index29 19,21,23,25,27
Mood and anxiety PRIME-MD15 2,4,6,8,10,12
Patient Health Questionnaire16,17 14,16,18,20,21,23,25 27
CES-Depression Scale18,19 all odd visits 1-27
Zung Anxiety Scale20 all odd visits 1-27
Perceived Stress (PSS)21 2,4,6,8,10,12,3–27 (odd visits)
Quality of Life Q-les-Q22 all odd visits
Utian QOL Scale23 21,25,27




Libido all odd visits 1-27
Vaginal Urinary Tract Rating
(BFLUTS-SF)38 21,24,26,28
Interview Questionnaire
Dryness odd visits 3-27
Urine leaks odd visits 3-27
Social support Interview Questionnaire 1, 9, 15, 19
Social Adjustment Scale31 1,3,5,11,13,15,22
Life Events 9,11,13,17,21,24,25,27






Questionnaire39 4, 10, 12, 14, 18
Interview Questionnaire 3,5,7,11,15,19-17 (odd)
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throughout the study. Incentives were provided to the
participants, such as a small payment and a gift (e.g.,
mugs, magnets, throws, etc.) at the completion of each
visit. In the intervals between the annual follow-up as-
sessments, study staff maintained contact with partici-
pants by sending birthday cards and holiday cards each
year. Participants were closely monitored via mailings
and telephone calls around the dates of estimated men-
ses in order to schedule visits on days 2–6 of the men-
strual cycle. If a participant could not be located by mail
or telephone, an interviewer went to the most recent
home address to make contact and/or to query neigh-
bors for information to locate the participant.
Data management
Two separate but related database management systems
were established. The first Management Information Sys-
tem (MIS) addressed the internal study procedures. This
included a database of all eligible women with the phone
numbers, addresses, and persons who could be contacted
on their behalf if the participant could not be located. The
database also included a full register of the menstrual
cycle dates reported by each participant at each visit and a
record of the blood collections as they were stored in
freezers or sent for assay. This database was used by the
study coordinator to track and schedule the study visits,
to identify the freezer location of blood samples, and to
select and batch blood samples for laboratory assays.
The second MIS contained all interview and questionnaire
data collected for the study. These data were coded as they
were collected and entered into computer files. A computer
technician performed range checks and other organizing
procedures to prepare the data for statistical analysis.
Potential bias and quality control
Menopausal symptom assessment is inherently based on
subjective perception. In order to limit expectancy effects
of menopause, the participants were told that the study
was a women’s health study. Specific questions about
menopause were embedded in questionnaires with many
other health questions. The menopause symptom ques-
tionnaire was validated and administered within the much
longer structured Interview Questionnaire that assessed
many aspects of women’s health. We assessed the major
symptoms of interest with both structured interview ques-
tions and more detailed validated self-report measures.
To reduce recall bias, the reference time frame for symp-
toms information was current, the data were collected con-
currently with the blood draws, and participants additionally
rated symptoms prospectively in daily symptom reports for
one menstrual cycle (or month) at each assessment period.
To control for menstrual cycle effects in the hormone
measures, all data were collected in the first 6 days of the
menstrual cycle in cycling women. Neither the interviewers
nor the participants had information from the study on the
participants’ hormone levels, making it unlikely that the
women reported their symptoms based on hormone
information.
To assure systematic data collection, we used struc-
tured interviews, and the interviewers were trained in the
use of standard probes. Review sessions were conducted
with the interviewers on an ongoing basis as part of the
quality control process to address problems, develop con-
sistent probes and promote systematic data collection. All
interviewers were trained for SCID interviews via taped
SCID interviews and training sessions with an experienced
SCID interviewer. Interviewers checked that data for com-
pletion at each home visit. In addition, the study coordin-
ator further reviewed all collected data when the data
were returned to the research site. In the event of missing
Table 1 Outcome measures by study visits (Continued)
Anthropomorphic Measurement:
Height, weight, waist, hip all odd visits 1-27
Wrist 23,25,27




Sex hormone binding globulin all visits 13-28
Anti-mullerian hormone V1 to variousendpoints
Genotypes 413 participants
Table 2 Study continuation and attrition by assessment period
PERIOD CONTINUING, N (%) DROPPED, N (%)
1 436 __
2 394 (90) 42 (10)
3-4 366 (84) 28 (6)
5-6 353 (84) 13 (3)
7-8 320 (73) 33 (8)
9-10 311 (71) 9 (2)
11-12 301 (69) 10 (2)
13-14 293 (67) 8 (2)
TOTAL 293 (67) 143 (33)
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data, interviewers re-contacted participants to complete
the missing items.
Representativeness of the cohort
The cohort participants were randomly identified by
random digit dialing in a large metropolitan area of the
U.S., with stratification to obtain equal numbers of African
American and Caucasian women. The exclusion criteria
limited the cohort to healthy women with a uterus and
ovary at enrollment. Consequently the data are generalizable
to generally healthy African American and Caucasian
women in large urban areas of the U.S. who experience
natural menopause. Findings may not be generalized to
other racial groups or to women with surgical meno-
pause, hormone users, serious illnesses or chronic dis-
ease without further studies.
Discussion
The POAS cohort was established to address the limited
scientific understanding of menopausal hormone changes
and symptoms and their relationships to health and
morbidity of mid-life women. The cohort followed the
large epidemiologic Study of Women’s Health Across
the Nation (SWAN), with specific aims to evaluate an
earlier baseline of symptoms and hormones in late re-
productive age women before they entered the transition to
menopause. Annual evaluations followed the participants
as they traversed the menopause transition. After 18 years
of follow-up, the cohort remains viable with adequate
statistical power for studies of the natural menopause
transition and early postmenopausal years.
Strengths of the cohort addressed several limitations of
earlier studies. The longitudinal data identified menopausal
stages as they were observed rather than by long-term recall.
Menopausal stages were based on the initial STRAW [42],
utilizing bleeding patterns to classify premenopausal, transi-
tion and postmenopausal stages. Hormone levels and symp-
toms were measured concurrently. To control for menstrual
cycle effects, all data, including the blood samples, were col-
lected within days 2–6 of the menstrual cycle in cycling
women. Menopausal stage was determined annually and, to-
gether with calendar age, can be analyzed to identify the in-
dependent effects of these key markers of menopausal
status. Longitudinal assessments from a premenopausal
baseline allowed new-onset symptoms to be identified in the
menopause transition. Extensive symptom assessments in-
cluded identifying psychiatric diagnoses to more clearly in-
terpret menopausal symptoms. The cohort was population-
based, participants were randomly-identified and in general
good health for this study of behavioral and hormonal fac-
tors in relation to natural menopause.
Limitations to consider include the following: the cohort
includes only Caucasian and African American women,
who were enrolled in equal numbers, and does not include
other racial or ethnic groups. Blood samples were col-
lected in the early follicular phase of the menstrual cycle
(days 2–6) to control for menstrual cycle effects, but do
not include luteal phase measures and cannot describe
across-cycle hormone effects. Hysterectomy and hormone
use were exclusions at enrollment and in subsequent
follow-up did not occur in sufficient numbers to analyze
these factors. Attrition naturally occurred over the 18 years
of follow up (described above), but the cohort remains
viable with adequate statistical power.
More than 50 studies based on this cohort are published
in medical journals at this time, demonstrating the rele-
vance of these data to the clinical care of mid-life women.
(See Additional file 1: Appendix 1). Several examples of
the POAS data as they elucidate clinical issues are the fol-
lowing: studies of the timing and duration of hot flashes
show that hot flashes can occur well before menopause
and extend 10 or more years beyond menopause for
sizeable numbers of women [48, 49]; data provide evi-
dence for new-onset depressed mood in the menopause
transition and show that the final menstrual period is piv-
otal in the premenopausal increase and postmenopausal
decrease in depressive symptoms [44, 50, 51]; data show
that poor sleep is common in the late reproductive years
but suggest that only a small proportion of women experi-
ence increases in poor sleep in relation to the final men-
strual period [28]; studies provide evidence of effects of
obesity on reproductive hormones in the menopause tran-
sition [45, 52]; show the relationship between smoking
and hot flashes as a function of genetic variation in sex-
steroid metabolizing enzymes [46, 53]; indicate decreased
libido in the menopause transition [54, 55]; menopause ef-
fects on verbal memory [56]; and anti-mullerian hormone
as a predictor of time to menopause [57, 58].
In conclusion, longitudinal data are critical for the
understanding of hormone changes and symptoms that
are experienced by mid-life women and influence other
physical conditions of aging. The POAS cohort and
other recent cohorts of mid-life women exist to address
questions about these menopausal changes. Increasing
scientific information about the biological and behav-
ioral changes associated with menopause contributes to
improving the health care of women.
Additional file
Additional file 1: Appendix 1. Publications of Data from the Penn
Ovarian Aging Study (POAS). ( DOC 29.2 KB)
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